Collecting data on advanced and rare cancers treated with personalized medicine
Official title: UNIQUE: Umbrella N-of-1 Tumor Trials - Umbrella Protocol for Oncology Single Patient Protocols
Run by University Health Network, Toronto · NCT06285500 · Data updated 2026-11-12
This study is trying to see how people with advanced and rare cancers respond to personalized treatments when they have run out of other options.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | University Health Network, Toronto Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Status | Recruiting |
| Started | February 1, 2024 |
| Main results expected | February 1, 2027 |
| Study ends | February 1, 2029 |
| Registry record updated | December 16, 2025 |
| Trial ID | NCT06285500 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with advanced cancer or rare diseases who have exhausted all standard treatment options.
✕Probably not a fit
Patients who are eligible for ongoing clinical trials or have not yet exhausted standard treatment options may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to gather information on how patients with advanced and rare cancers respond to biomarker-based treatments through a unique umbrella protocol. It focuses on individuals who have exhausted all standard treatment options and are not eligible for ongoing trials. Participants will be assigned to cohorts based on their treatment history, which may include standard care drugs, special access drugs, or investigational agents. Data collected will include demographic information, medical history, cancer characteristics, and treatment responses.
Why it matters
Potential benefit: If successful, this study could lead to more effective personalized treatment options for patients with advanced and rare cancers.
How similar studies have gone: Other studies utilizing precision medicine approaches have shown promise, indicating potential for success in this novel framework.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria \& Exclusion Criteria: Patient's existing genomic information from tumor molecular profiling will be discussed in the hospital expert molecular tumor board rounds consisting of representatives from specialist genomic profiling and medical oncology departments to decide N of 1 treatment for the patient. The discussion will surround the best next therapeutic option in the patient's cancer subtype with or without clear standard of care guidelines. Therefore, specific eligibility criteria aside from individual patient's medical history is not applicable.
Where it's running
-
University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario, Canada Recruiting
Study contacts
- Principal investigator: Amit Oza, Dr. — University Health Network, Toronto
- Study coordinator: Amit Oza, Dr.
- Email: amit.oza@uhn.ca
- Phone: 416 946 4450
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Concise coaching to guide decisions for advanced cancer patients considering palliative procedures
A coaching program delivered by lay providers will test whether it helps adults with advanced cancer make better, patient-aligned decisions about palliative surgeries or similar interventions.
-
Primary Palliative Care: A Feasibility Project for Family Health Units
This feasibility trial tests a GP training program plus a structured 12-week palliative-care visit plan to see if it can be carried out in primary care for adults with advanced illness.
-
Virtual Group Resilient Living for Advanced Cancer
A group-based online program tests whether seven weekly sessions can reduce anxiety and fatigue and improve quality of life for adults with advanced cancer.
-
AI-assisted Rare-Disease Diagnosis
A multicenter randomized test to see if an AI diagnostic tool can help doctors make faster, more accurate rare-disease diagnoses for patients with unresolved symptoms.
-
IV contrast-enhanced CBCT with HyperSight for image guidance in advanced cancer radiotherapy
This study tests whether giving IV contrast during cone-beam CT helps doctors see the tumor better during radiotherapy in people with advanced cancer.
-
Single-session celiac plexus SBRT using a simulation-free adaptive workflow for cancer-related pain
A pilot test to see if a one-day, simulation-free adaptive radiotherapy process can safely deliver celiac plexus SBRT to adults with advanced pancreatic or other cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.